Novo aims to diversify with new pipeline assets and bolt-on deals
At its capital markets day Novo unveiled pipeline-diversification and bolt-on deal plans, but shares slid 5% as investors wanted bigger swings.
Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.
Company Info
Sector:Pharmaceuticals / Diabetes & Obesity
Headquarters:Bagsværd, Denmark
Founded:1923
Website:www.novonordisk.com/
Upcoming Milestones & Key Dates
Q2 2026
Earnings
Q2 2026 earnings reported; CagriSema Phase 3 readout timeline update
2026
Conference
Cardiovascular outcomes data and pipeline updates across cardiometabolic franchise
Clinical Development Pipeline
Wegovy (semaglutide 2.4 mg)
Target: GLP-1 receptor agonistCagriSema (semaglutide + cagrilintide)
Target: GLP-1 / amylin receptor agonist combinationOzempic (semaglutide injectable)
Target: GLP-1 receptor agonistRecent News
CHMP backs Novo’s hemophilia A drug and seven other medicines
The EU's CHMP has backed Novo's hemophilia A medicine along with seven other products.
Novo drops Nordisk moniker, turns bull toward future in company rebrand
Novo Nordisk has officially dropped the Nordisk from its corporate name as part of a broader rebranding initiative.
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
Wegovy helps free 40% of kids from obesity in phase 3 trial
Wegovy helps free 40% of kids from obesity in phase 3 trial
Prospects for Novo's CKD program narrow as ph. 3 trials scrapped
Novo Nordisk's blockbuster hopes for its chronic kidney disease program dwindle after additional Phase 3 trials are scrapped.
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
China's drug regulator accepts Novo Nordisk's application for oral Wegovy
China's drug regulator accepts Novo Nordisk's application for oral Wegovy
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
Novo and Amazon sign drug discovery pact, launch innovation hub
Novo and Amazon sign drug discovery pact, launch innovation hub
Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Novo Nordisk makes Omnicom agency of record for US media buying
Novo Nordisk makes Omnicom agency of record for US media buying
Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
Novo setback casts doubt on a new way to treat heart disease
Novo setback casts doubt on a new way to treat heart disease
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
Novo Nordisk CEO Maziar Mike Doustdar says the company is focused on building out its pipeline to move past recent clinical roadblocks.
Novo's late-stage IL-6 stumble shakes inflammation space
Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week's Phase 3 failure dashed not just the Danish pharma's hopes but those of the broader inflammatio
Novo Nordisk rocked by late-stage cardiovascular drug failure
Novo Nordisk's cardiovascular pipeline suffered a late-stage clinical failure, a setback for the company's expansion beyond diabetes and obesity.
US judge says Novo Nordisk must face lawsuit over CagriSema
US judge says Novo Nordisk must face lawsuit over CagriSema
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
A federal judge denied Novo Nordisk's motion to dismiss a securities class action lawsuit over its 2024 CagriSema obesity-pipeline readout, allowing the case to proceed.
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court. Reported by BioSpace on 2026-07-29.
Novo sues Lilly, alleging 'misleading' advertising of obesity drugs
Novo Nordisk is suing Eli Lilly, alleging 'misleading' advertising of obesity drugs.
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
Novo Nordisk sued Eli Lilly over what it calls 'deceptive' ads comparing GLP-1 drug doses.
Novo Nordisk expands in China and Czech; Cellares boosts Series D by $50M
Novo Nordisk expands in China and Czech; Cellares boosts Series D by $50M — Endpoints News coverage of biopharma industry developments.